Inozyme Pharma Inc (INZY) Is A Buy According To Analysts
Inozyme Pharma Inc (NASDAQ:INZY) has a beta value of 2.29 and has seen 1.02 million shares traded in the last trading session. The company, currently
Inozyme Pharma Inc (NASDAQ:INZY) has a beta value of 2.29 and has seen 1.02 million shares traded in the last trading session. The company, currently
During the last session, Inozyme Pharma Inc (NASDAQ:INZY)’s traded shares were 3.82 million, with the beta value of the company hitting 2.22. The 52-week high
In the last trading session, 1.14 million shares of the Inozyme Pharma Inc (NASDAQ:INZY) were traded, and its beta was 2.07. Most recently the company’s
Inozyme Pharma Inc (NASDAQ:INZY)’s traded shares stood at 2.56 million during the last session, with the company’s beta value hitting 2.37.The INZY share’s 52-week high
In the last trading session, 49.75 million Inozyme Pharma Inc (NASDAQ:INZY) shares changed hands as the company’s beta touched 1.42. With the company’s per share
Inozyme Pharma Inc (NASDAQ:INZY) has a beta value of 1.31 and has seen 0.66 million shares traded in the recent trading session. The INZY stock
In the last trading session, 1.88 million shares of the Inozyme Pharma Inc (NASDAQ:INZY) were traded, and its beta was 1.35. Most recently the company’s
In the last trading session, 8.1 million shares of the Inozyme Pharma Inc (NASDAQ:INZY) were traded, and its beta was 1.38. Most recently the company’s
In last trading session, Inozyme Pharma Inc (NASDAQ:INZY) saw 0.33 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price
© 2024, Powered by Smart TechOne